Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For Cohort 1 and 2: (Recruitment ended by 02/20/2020)
Advanced melanoma (Stage III/Stage IV)
Histologically confirmed diagnosis
Treatment decision for nivolumab monotherapy or nivolumab/ipilimumab combination therapy has already been taken
For Cohort 3: (Recruitment ended by 08/31/2020)
Primary diagnosis of advanced melanoma after complete surgical tumor resection and no evidence of disease
Treatment decision for adjuvant nivolumab therapy has already been taken
You may not be if
For Cohort 1 and 2: (Recruitment ended by 02/20/2020)
Current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator)
Previous treatment with nivolumab, for nivolumab monotherapy cohort only
Current active participation in an interventional clinical trial
For Cohort 3: (Recruitment ended by 08/31/2020)
Current diagnosis of persisting advanced melanoma or a cancer other than advanced melanoma that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator)
Current active participation in an interventional clinical trial
Clareo Health | Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
